Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where George Ku is active.

Publication


Featured researches published by George Ku.


FEBS Letters | 1992

A protective role for nitric oxide in the oxidative modification of low density lipoproteins by mouse macrophages

Mark T. Yates; Laurie E. Lambert; Jeffrey P. Whitten; Ian A. McDonald; Masayuki Mano; George Ku; Simon J.T. Mao

Low density lipoproteins (LDL) oxidatively modified by macrophages have been shown to be atherogenic in ex vivo studies. We studied the potential role of nitric oxide (NO), a free radical produced by macrophages, in LDL modification. Human LDL (1 mg/ml) were incubated with mouse peritoneal macrophages in Hams F‐10 medium. The cells were then stimulated by interferon‐γ and tumor necrosis factor‐α to increase their production of NO from 1.3 to 12.2 μM in 24 h, as measured by nitrite. Lipid peroxidation of LDL, as measured by thiobarbituric acid‐reactive materials (TBARS), was reduced in stimulated cells in a time‐dependent manner. At 24 h, the decrease was about 27%. In the presence of an NO synthase inhibitor (No‐aminophomoarginine), the generation of NO was diminished and the protection against LDL lipid peroxidation was reversed. The extent of LDL protein modification was also assessed by examining its electrophoretic mobility. It was found that macrophage NO reduced the change in LDL electromobility. These data indicate that the production of NO may inhibit the oxidative modification of LDL with cytokine‐stimulated macrophages. We suggest that NO plays a protective role in limiting macrophage‐induced LDL modification.


American Journal of Cardiology | 1988

Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis

George Ku; Niall Doherty; Jeffrey A. Wolos; Richard L. Jackson; Lisa F. Schmidt; Deborah Hendricks

Intravenous injection of 1.5 mg of acetylated low-density lipoprotein (LDL) or 100 micrograms of lipopolysaccharide (LPS) to zymosan-primed mice induced a decrease in serum zinc levels measured 6 hours after injection, suggesting the release of interleukin 1 (IL-1). Oral administration of probucol, 100 mg/kg once daily for 14 days, inhibited the LPS-induced fall in serum zinc levels, suggesting inhibition of IL-1 release. Direct evidence for inhibition of IL-1 release by probucol was obtained with an ex vivo system in which, compared with controls, peritoneal macrophages from probucol-treated mice (100 mg/kg orally X 3, or 0.25% in the diet for 3 weeks) secreted 80 to 90% less IL-1 upon LPS stimulation, measured by the C3H/HeJ thymocyte proliferation assay. Inhibition of IL-1 secretion by probucol may contribute to the therapeutic effect of probucol in atherosclerosis since as little as 1 unit of recombinant IL-1 beta was found to induce proliferation of aortic smooth muscle cells. With regard to the endogenous stimulus for IL-1 secretion, oxidized LDL is a putative candidate because it is capable of stimulating peritoneal macrophages to secrete IL-1. Because oxidized LDL is involved in the transformation of macrophages to foam cells, our data on IL-1 induction by oxidized LDL and the mitogenic effect of IL-1 on aortic smooth muscle cells suggest that activated macrophages play an important role in atherogenesis.


Atherosclerosis | 1990

Probucol does not alter acetylated low density lipoprotein uptake by murine peritoneal macrophages

George Ku; Kendra Schroeder; Lisa F. Schmidt; Richard L. Jackson; Niall Doherty

It has been suggested that the anti-atherogenic effect of probucol (MDL 11,309) in familial hypercholesterolemic rabbits may be due in part to the inhibition of the uptake of modified low density lipoproteins by macrophages in the arterial wall. To test this hypothesis, mice were treated with dietary probucol (0.25%) for fourteen days, peritoneal macrophages were isolated and the uptake of acetylated low density lipoprotein (ALDL) was studied. In addition, peritoneal macrophages from control animals were treated with probucol (200 micrograms/ml) for 24 h in vitro prior to the ALDL uptake assay. The assay involved a fluorescent ALDL probe (dioctadecyltetramethylindocarbocyanine perchlorate-labeled ALDL), and measurement of uptake with a flow cytometer. No differences in ALDL uptake were detected between the control macrophages and macrophages treated with probucol in vitro or macrophages taken from probucol-treated mice.


Bioorganic & Medicinal Chemistry Letters | 1993

Synthesis and biological activity of sulfoximine-modified myristic acid analogues

Ian A. McDonald; Philip L. Nyce; George Ku; Terry L. Bowlin

Abstract Analogues of myristic acid, incorporating a sulfoximine structure in place of the carboxylic acid moiety, were synthesized and found to inhibit some biological processes that are dependent upon a myristoylation event.


Medicinal Research Reviews | 1993

Antioxidants : a biological defense mechanism for the prevention of atherosclerosis

Richard L. Jackson; George Ku; Craig E. Thomas


Archive | 1988

Method of inhibiting interleukin-1 release

George Ku; Niall Doherty


Archive | 1990

Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions

George Ku; Niall Doherty


Archive | 1992

Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock

Albert A. Carr; Craig E. Thomas; Ronald C. Bernotas; George Ku


Archive | 1988

Alkylidenedithiobis (substituted) phenols for inhibiting interleukin-1 release and for alleviating interleukin-1 mediated conditions

George Ku; Niall Doherty


Archive | 1994

Cyclic nitrone compounds useful in treating stroke

Albert A. Carr; Craig E. Thomas; Ronald C. Bernotas; George Ku

Collaboration


Dive into the George Ku's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge